Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00MBY
|
|||
| Former ID |
DIB014904
|
|||
| Drug Name |
AAD-2004
|
|||
| Synonyms |
AAD-2004; 927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
GNT Pharma Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H14F3NO3
|
|||
| Canonical SMILES |
C1=CC(=CC=C1CCNC2=CC(=C(C=C2)O)C(=O)O)C(F)(F)F
|
|||
| InChI |
1S/C16H14F3NO3/c17-16(18,19)11-3-1-10(2-4-11)7-8-20-12-5-6-14(21)13(9-12)15(22)23/h1-6,9,20-21H,7-8H2,(H,22,23)
|
|||
| InChIKey |
UTMVACIBQLDZLP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 927685-43-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin E synthase (PTGES) | Target Info | Inhibitor | [1] |
| BioCyc | C20 prostanoid biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Arachidonic acid metabolism | |||
| Eicosanoid Synthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012 Sep;122(5):952-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.